Skip to main content
Sign In

University of Colorado Denver

University of Colorado Denver School of Medicine
 

Lynn E. Heasley

Professor and Chair


Lynn Heasley
Dr. Lynn E. Heasley

Department of Craniofacial Biology
School of Dental Medicine
Mail Stop 8120
12801 E. 17th Avenue
Aurora, CO  80045

Phone: 303-724-4578
Fax: 303-724-4580
Email: lynn.heasley@ucdenver.edu

Education:

  • Postdoctoral Fellow, Division of Basic Sciences, National Jewish Center for Immunology and Respiratory Medicine, Denver, CO
  • Postdoctoral Fellow, Department of Biochemistry, University of Massachusetts Medical Center, Worcester, MA
  • PhD, Pharmacology, University of California at San Diego, La Jolla, CA
  • BA, Chemistry/Biology, Point Loma College, San Diego, CA

Honors and Awards:

  • VA Merit Researcher, Eastern Colorado VA
  • Full Member, NIH Tumor Cell Biology Study Section
  • Editorial Board, the Journal of Biological Chemistry

Departmental Affiliations:

  • Department of Craniofacial Biology, School of Dental Medicine
  • Department of Pharmacology, School of Medicine

Research Interests

  • Lung Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Receptor Tyrosine Kinase Signaling Networks
  • Functional Genomics and Synthetic Lethal Screens
  • Experimental Therapeutics with Pipeline and Investigational Cancer Drugs

Recent Publications:

  • Singleton KR, Hinz TK, Kleczko EK, Marek LA, Kwak J, Harp T, Kim J, Tan AC and Heasley LE. (2015) Kinome RNAi screens identify MTOR for synergistic targeting with FGFR1 in lung cancer and HNSCC cell lines. Cancer Research. 75(20):4398-406.
  • Ryall KA, Shin J, Yoo M, Hinz TK, Kim J, Kang J, Heasley LE, and Tan AC. (2015) Identifying kinase dependency in cancer cells by integrating highthroughput drug screening and kinase inhibition data. Bioinformatics. 31(23):3799-3806.
  • Göke, F. Franzen, A, Hinz, TK, Marek, LA, Yoon, P, Sharma, R, Bode, M, von Maessenhausen, A, Lankat-Buttgereit, B, Göke, A, Golletz, C, Kirsten, R, Boehm, D, Vogel, W, Kleczko, EK, Eagles, JR, Hirsch, FR, Van Bremem, T, Bootz, F, Schroeck, A, Ta, AC, Jimeno, A, Heasley, LE and Perner, S. (2015) FGFR1 expression levels predict BGJ398-sensitivity of FGFR1-dependent head and neck squamous cell cancers. Clin Cancer Res. 21(19):4356-64.
  • Kleczko EK, Kim J, Keysar SB, Heasley LR, Eagles JR, Simon M,. Marshall ME, Singleton KR, Jimeno A, Tan AC, and Heasley LE. (2015) An inducible TGF-β2-TGFβR pathway modulates the sensitivity of HNSCC cells to tyrosine kinase inhibitors targeting dominant receptor tyrosine kinases. PLoS One 10(5):e0123600.
  • Marek, L, Hinz, TK, von Massenhausen, A, Olszewski, KA, Kleczko, EK, Bohm, D, Weiser-Evans, MCM, Nemenoff, RA, Hoffmann, H, Warth, A, Gozgit, JM, Perner, S and Heasley, LE. (2014) Non-amplified FGFR1 is a growth driver in malignant pleural mesothelioma cells. Mol. Cancer Res. 12:1460-9.
  • Kim J, Vasu VT, Mishra R, Singleton KR, Yoo M, Leach SM, Farias-Hesson E, Mason RJ, Kang J, Ramamoorthy P, Kern JA, Heasley LE, Finigan JH, Tan AC. (2014) Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy. Bioinformatics. 30(17):2393-8.
  • Wynes, M, Hinz, TK, MW, Gao, D, Martini, M, , Marek, LA, Ware, KE, Edwards, MG, Böhm, D, Perner, S, Helfrich, BA, Dziadziuszko, R, Jassem, J, Wojtylak, S., Sejda, A., Bunn, PA Jr,  Gozgit, JM, Camidge, DR, Tan, AC, Hirsch, FR and Heasley, LE. (2014) FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin. Cancer Res. 20(12):3299-309.
  • von Mässenhausen A, Franzen A, Heasley LE, Perner S. (2013) FGFR1 as a novel prognostic and predictive biomarker in squamous cell cancers of the lung and the head and neck area. Ann Transl Med 1(3):23.
  • Göke F, Bode M, Franzen A, Kirsten R, Goltz D, Göke A, Sharma R, Boehm D, Vogel W, Wagner P, Lengerke C, Kristiansen G, Kirfel J, Van Bremen T, Bootz F, Heasley LE, Schröck A, Perner S. (2013) Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck. Mod Pathol. 26(10):1298-306.
  • Singleton KR, Kim J, Hinz TK, Marek LA, Casas-Selves M, Hatheway C, Tan AC, DeGregori J, Heasley LE. (2013) A receptor tyrosine kinase network comprised of FGFRs, EGFR, ERBB2 and MET drives growth and survival of head and neck squamous carcinoma cell lines.  Mol Pharmacol 83(4):882-93.
  • Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA, Cummings CT, Graham DK, Astling D, Tan AC, Heasley LE. (2013) A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis 2:e39.